Your browser doesn't support javascript.
loading
Pluripotent stem cell-derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction.
Thavapalachandran, Sujitha; Le, Thi Yen Loan; Romanazzo, Sara; Rashid, Fairooj N; Ogawa, Masahito; Kilian, Kristopher A; Brown, Paula; Pouliopoulos, Jim; Barry, Anthony M; Fahmy, Peter; Kelly, Kilian; Kizana, Eddy; Chong, James J H.
Afiliación
  • Thavapalachandran S; Centre for Heart Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia; Department of Cardiology, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
  • Le TYL; Centre for Heart Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia; Australian Nuclear Science and Technology Organisation, Sydney, Australia.
  • Romanazzo S; School of Chemistry, School of Materials Science and Engineering, Australian Centre for NanoMedicine, University of New South Wales, Sydney, Australia.
  • Rashid FN; Centre for Heart Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
  • Ogawa M; Centre for Heart Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
  • Kilian KA; School of Chemistry, School of Materials Science and Engineering, Australian Centre for NanoMedicine, University of New South Wales, Sydney, Australia.
  • Brown P; Department of Cardiology, Westmead Hospital, Sydney, Australia.
  • Pouliopoulos J; Department of Cardiology, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
  • Barry AM; Department of Cardiology, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
  • Fahmy P; Department of Cardiology, Westmead Hospital, Sydney, Australia.
  • Kelly K; Cynata Therapeutics Limited, Melbourne, Australia.
  • Kizana E; Centre for Heart Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia; Department of Cardiology, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
  • Chong JJH; Centre for Heart Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia; Department of Cardiology, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia. Electronic address: james.chong@sydney.edu.au.
Cytotherapy ; 23(12): 1074-1084, 2021 12.
Article en En | MEDLINE | ID: mdl-34588150
BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) have been shown to improve cardiac function after injury and are the subject of ongoing clinical trials. In this study, the authors tested the cardiac regenerative potential of an induced pluripotent stem cell-derived MSC (iPSC-MSC) population (Cymerus MSCs) in a rat model of myocardial ischemia-reperfusion (I/R). Furthermore, the authors compared this efficacy with bone marrow-derived MSCs (BM-MSCs), which are the predominant cell type in clinical trials. METHODS: Four days after myocardial I/R injury, rats were randomly assigned to (i) a Cymerus MSC group (n = 15), (ii) a BM-MSC group (n = 15) or (iii) a vehicle control group (n = 14). For cell-treated animals, a total of 5 × 106 cells were injected at three sites within the infarcted left ventricular (LV) wall. RESULTS: One month after cell transplantation, Cymerus MSCs improved LV function (assessed by echocardiography) compared with vehicle and BM-MSCs. Interestingly, Cymerus MSCs enhanced angiogenesis without sustained engraftment or significant impact on infarct scar size. Suggesting safety, Cymerus MSCs had no effect on inducible tachycardia or the ventricular scar heterogeneity that provides a substrate for cardiac re-entrant circuits. CONCLUSIONS: The authors here demonstrate that intra-myocardial administration of iPSC-MSCs (Cymerus MSCs) provide better therapeutic effects compared with conventional BM-MSCs in a rodent model of myocardial I/R. Because of its manufacturing scalability, iPSC-MSC therapy offers an exciting opportunity for an "off-the-shelf" stem cell therapy for cardiac repair.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Pluripotentes Inducidas / Células Madre Mesenquimatosas / Infarto del Miocardio Límite: Animals Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Pluripotentes Inducidas / Células Madre Mesenquimatosas / Infarto del Miocardio Límite: Animals Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido